## 2, 2001 1100011109 2001100 11001

## **CLAIM SET AS AMENDED**

- 1. (Withdrawn) A solid pharmaceutical preparation comprising at least one at least partially charged active substance, wherein the active substance is present in form of a nanosol in which the active substance is bonded to an oppositely charged chitosan derivative.
- 2. (Withdrawn) The solid pharmaceutical preparation according to Claim 1, wherein the active substance possesses a positive charge and is bonded to a zwitterionic, acidic chitosan derivative.
- 3. (Withdrawn) The solid pharmaceutical preparation according to Claim 1, wherein the active substance possesses a negative charge and is bonded to a basic chitosan derivative.
- 4. (Withdrawn) The solid pharmaceutical preparation according to claim 1, wherein the active substance and the chitosan derivative are present in the nanosol in almost isoionic state.
- 5. (Withdrawn) The solid pharmaceutical preparation according to claim 1, wherein the active substance is present in the nanosol in colloidal or in nanoparticulate form.

- 6. (Withdrawn) The solid pharmaceutical preparation according to claim 1, wherein the active substance is poorly soluble.
- 7. (Withdrawn) The solid pharmaceutical preparation according to claim 1, wherein it contains a further polymeric carrier substance apart from the chitosan derivative.
- 8. (Withdrawn) The pharmaceutical preparation according to claim 1, wherein the preparation is used for the production of a medicinal product.
- 9. (Withdrawn) The pharmaceutical preparation according to claim 1, wherein the preparation is used for the production of a medicinal product for peroral application.
- 10. (Withdrawn) The pharmaceutical preparation according to claim 8, wherein the preparation is used for the production of a medicinal product that is administered as a powder, granulate, tablet or capsule.
- 11. (Withdrawn) The pharmaceutical preparation according to claim 8, wherein the medicinal product which, for the purpose of administration, is dissolved or redispersed in a liquid.

- 12. (Withdrawn) The pharmaceutical preparation according to claim 8, wherein the medicinal product has controlled active substance release.
- 13. (Withdrawn) The pharmaceutical preparation according to claim 1, wherein the preparation is used for the production of a diagnostic agent.
- 14. (Currently Amended) A process for the production of a solid pharmaceutical preparation comprising at least one at least partially charged active substance, which active **substance** is present in the form of a **dried** nanosol in which the active substance is bonded to an oppositely charged chitosan derivative, which comprises:
- a) selecting a chitosan derivative according to the type and relative number of its charged groups and in coordination with the type and relative number of the charged groups of the active substance such that at a certain pH value an isoionic state or charge equalization between active substance and carrier can be achieved in the preparation,
- b) preparing an aqueous sol containing the active substance from the chitosan derivative **and the active substance**,
- c) adjusting the pH value of the aqueous sol such that an isoionic state results, possibly with colloidal or nano-scale active substance particles precipitating, and

Amendment dated May 12, 2004 Appl. No. 10/069,400 Reply to Office Action of Feb. 12, 2004 Attorney Docket No.: 3868-0109P

d) drying the thus-adjusted thus-obtained aqueous sol nanosol.

15.(Previously Presented) The process according to claim 14, wherein said active substance possesses a positive charge and is bonded to a zwitterionic, acidic chitosan derivative.

16.(Previously Presented) The process according to claim 14, wherein said active substance possesses a negative charge and is bonded to a basic chitosan derivative.

17.(Previously Presented) The process according to claim 14, wherein said active substance is poorly soluble.

18.(Currently Amended) The process according to claim 14, wherein a comprising an additional step of adding a further polymeric carrier substance is used apart from the chitosan derivative.

19. (New) The process according to claim 14, wherein the nanosol has an average particle size at a maximum of about 500-1000 nm.